{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:41Z","timestamp":1776211241904,"version":"3.50.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,5,7]]},"DOI":"10.1001\/jama.2019.4973","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T23:07:19Z","timestamp":1557270439000},"page":"1693","source":"Crossref","is-referenced-by-count":28,"title":["Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease"],"prefix":"10.1001","volume":"321","author":[{"given":"Robert A.","family":"Wise","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Chapman","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami Z.","family":"Daoud","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development Centre, Gaithersburg, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Zetterstrand","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development, Bioinformatics and Information Sciences, M\u00f6lndal, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Reisner","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development Centre, Gaithersburg, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Garcia","family":"Gil","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development Centre, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"joi190041r2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.annepidem.2005.04.008","article-title":"Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients.","volume":"16","author":"Curkendall","year":"2006","journal-title":"Ann Epidemiol"},{"issue":"6","key":"joi190041r3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1183\/09031936.00133805","article-title":"Mortality in COPD: role of comorbidities.","volume":"28","author":"Sin","year":"2006","journal-title":"Eur Respir J"},{"issue":"5","key":"joi190041r4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD.","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"issue":"12","key":"joi190041r5","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.","volume":"300","author":"Singh","year":"2008","journal-title":"JAMA"},{"issue":"15","key":"joi190041r6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease.","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"joi190041r7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1056\/NEJMp1008502","article-title":"The safety of tiotropium\u2014the FDA\u2019s conclusions.","volume":"363","author":"Michele","year":"2010","journal-title":"N Engl J Med"},{"key":"joi190041r8","doi-asserted-by":"publisher","first-page":"d3215","DOI":"10.1136\/bmj.d3215","article-title":"Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials.","volume":"342","author":"Singh","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"joi190041r9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1183\/09031936.00005813","article-title":"Use of tiotropium Respimat soft mist inhaler versus HandiHaler and mortality in patients with COPD.","volume":"42","author":"Verhamme","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"joi190041r10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/thoraxjnl-2012-201926","article-title":"Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.","volume":"68","author":"Dong","year":"2013","journal-title":"Thorax"},{"issue":"10","key":"joi190041r11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1164\/rccm.200906-0876OC","article-title":"Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.","volume":"180","author":"Celli","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"joi190041r12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12931-015-0216-4","article-title":"Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT trial.","volume":"16","author":"Tashkin","year":"2015","journal-title":"Respir Res"},{"issue":"6","key":"joi190041r13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3109\/15412555.2016.1170111","article-title":"Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: a pooled analysis of five phase III, randomized, placebo-controlled studies.","volume":"13","author":"Wedzicha","year":"2016","journal-title":"COPD"},{"issue":"1","key":"joi190041r14","first-page":"5","article-title":"Long-term evaluation of the effects of aclidinium bromide on major adverse cardiovascular events and COPD exacerbations in patients with moderate to very severe COPD: rationale and design of the ASCENT COPD study.","volume":"5","author":"Wise","year":"2018","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"1","key":"joi190041r15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general US population.","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"joi190041r18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/pst.1624","article-title":"Missing data sensitivity analysis for recurrent event data using controlled imputation.","volume":"13","author":"Keene","year":"2014","journal-title":"Pharm Stat"},{"issue":"13","key":"joi190041r19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"joi190041r20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/bcp.v81.2","article-title":"Tiotropium Respimat vs HandiHaler: real-life usage and TIOSPIR trial generalizability.","volume":"81","author":"Schmiedl","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"joi190041r21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/thoraxjnl-2013-203724","article-title":"Limited generalisability of UPLIFT findings to clinical practice.","volume":"68","author":"Walker","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"joi190041r22","first-page":"435","article-title":"Overall and cardiovascular safety of aclidinium bromide in patients with COPD: a pooled analysis of six phase III, placebo-controlled, randomized studies.","volume":"3","author":"Chapman","year":"2015","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"2","key":"joi190041r23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study.","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"joi190041r24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.amjcard.2005.05.016","article-title":"Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention.","volume":"96","author":"Selvaraj","year":"2005","journal-title":"Am J Cardiol"},{"issue":"8","key":"joi190041r25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1513\/AnnalsATS.201710-815OC","article-title":"Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease.","volume":"15","author":"Rothnie","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"joi190041r26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00408-011-9301-8","article-title":"Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial.","volume":"189","author":"Halpin","year":"2011","journal-title":"Lung"},{"issue":"9","key":"joi190041r27","doi-asserted-by":"publisher","first-page":"e007824","DOI":"10.1136\/bmjopen-2015-007824","article-title":"Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis.","volume":"5","author":"Rothnie","year":"2015","journal-title":"BMJ Open"},{"issue":"10030","key":"joi190041r28","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"joi190041r29","first-page":"482","article-title":"Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.","volume":"10","author":"Cazzola","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"joi190041r1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed February 7, 2019."},{"key":"joi190041r16","unstructured":"HicksKA, HungHMJ, MahaffeyKW, . Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials. August 20, 2014:1-33. https:\/\/www.cdisc.org\/system\/files\/all\/standard\/Draft%20Definitions%20for%20CDISC%20August%2020%2C%202014.pdf. Accessed August 28, 2018."},{"key":"joi190041r17","unstructured":"US Food and Drug Administration. Guidance for Industry: Diabetes Mellitus\u2014Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071627.pdf. Accessed September 5, 2018."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jama\/article-pdf\/321\/17\/1693\/17555735\/jama_wise_2019_oi_190041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T23:07:25Z","timestamp":1557270445000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2019.4973"}},"subtitle":["The ASCENT-COPD Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,5,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.4973","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}